Document is current

Article History

Accepted: 24 October 2025

First Online: 8 December 2025

<!--Emphasis Type='Bold' removed-->Competing interests

: The ADQI consensus meeting was sponsored by Alexion, Baxter, Bioporto, BTG/SERB Pharmaceuticals, Calliditas, Medibeacon, Merck, Nova Biomedical, Novartis, Pfizer and SeaStar Medical. Sponsoring entities had no input in the discussions or in the final consensus statements or manuscript preparation. K.B. receives research support to her institution from StemLine Therapeutics. L.C. serves on the advisory boards of SERB and on speaker panels for SERB and Pfizer. She also serves as Editor-in-Chief of the Journal of Onco-Nephrology . R.F. had teaching honoraria from Vifor. M.F. serves on the advisory boards of GlaxoSmithKline and on speaker panels for Fresenius Medical Care, Jafron, B. Braun, Nipro and GlaxoSmithKline. He also serves on the editorial board for Kidney and Blood Pressure Research . L.G.F. reports research support from Baxter, Medibeacon, OrthoDiagnostics, SphingoTec and the NIHR. He has been on speaker panels for Fresenius Medical Care, Cytosorbents, SphingoTec and Vantive. I.G.G. reports an advisory board fee from T-knife Therapeutics, Inc. and support from NIH MSK Core Grant P30CA008748. S.L.G. receives consulting income from SeaStar Medical, BioPorto Diagnostics, Calcimedica, Mozarc Medical, Otsuka, Baxter Healthcare, Renibus Therapeutics and Novartis. He serves as a paid member of the Data Safety Monitoring Board for Silver Creek Therapeutics and Novartis. He serves on Speaker’s Panels for Baxter Healthcare and Fresenius Medical Care. He has stock options from MediBeacon, Inc. and serves as their Director of Clinical Development. He and his employer receive licensing royalties from RAIDAR Health. S.G. reports research support from the NIH, NIDDK K23DK125672 and R03DK141708. She also reports research funding from BTG International, Janssen, GE Healthcare and AstraZeneca, outside the submitted work. She is a consultant for Alexion, Mersana, MediBeacon and Orion Pharma. She founded and is Co-President Emeritus of the American Society of Onconephrology (unpaid). She also received speaker fees from Springer Inc. S.M.H. reports research support from Mayo Clinic Center for Clinical and Translational Science grant number UL1TR002377 and the Fulk Career Development Award. She serves as Review Section Editor for onconephrology for Nephrology Dialysis Transplantation . E.A.J. is supported by NIH grants R01DK129299 and P30CA008748. K.D.J. reports consultancy agreements with Novartis, Otsuka, Calliditas, George Clinicals, Vera Therapeutics and Travere Therapeutics; reports honoraria from the American Society of Nephrology and the International Society of Nephrology; is a paid contributor to UpToDate and is Section Editor for onconephrology for Nephrology Dialysis Transplantation ; serves on the editorial boards of American Journal of Kidney Diseases , CJASN , Clinical Kidney Journal , Frontiers in Nephrology , Journal of Onco-Nephrology and Kidney International ; and serves as the Editor-in-Chief of ASN Kidney News . S.K. reports consultancy agreement with George Clinicals, serves on the editorial boards of Advances in Kidney Disease and Health and Néphrologie et Thérapeutique , as a Review Editor for Frontiers in Nephrology and as a board member for the American Society of Onconephrology. A.K. administers funding from Amgen and Janssen for the University Health Network Onco-Nephrology Fellowship and serves as the President of the American Society of Onconephrology. H.J.L. receives research funding from Alexion (AstraZeneca), Nexcella, Janssen, Abbvie, Prothena and Protego. She has served in consultant/advisory roles to Alexion (AstraZeneca), Nexcella, Karyopharm, Arcellx, Abbvie and Pfizer. D.E.L. is supported by NIH grants R01DK125786, R01DK126685 and U01AG089040, has received research support from BioPorto, BTG International, Metro International Biotech LLC, Renibus Therapeutics, Inc. and Alexion Pharmaceuticals, has served as a consultant for Sidereal Therapeutics, MexBrain, Entrada Therapeutics, CardioRenal Systems, Inc. and Alexion Pharmaceuticals, and served as a Co-Chair of a Safety Monitoring Committee for EMD Serono Research and Development Institute, Inc. P.L. is an Associate Editor for Cardiorenal Medicine , Blood Purification and Frontiers in Nephrology and serves on the editorial board for the AKI section of the Journal of Nephrology . He has participated in speaker panels or advisory boards sponsored by AstraZeneca, Bayer, Jafron and GSK. J.M. is an editorial board member of Nephrology Dialysis Transplantation (Transplantation section). G.M. serves on the editorial boards of Kidney International , Kidney International Reports and the Journal of Onco-Nephrology . N.M. reports research support from NIH, R01DK137980; is a consultant for Otsuka, Asahi Kasei, Akebia and Sanofi; received honorarium from Elsevier; serves on the editorial board of Transplantation . M.O. received research funding from bioMérieux and Baxter, which was paid to the institution. A.P. has served on the advisory boards of GlaxoSmithKline, Otsuka, Astellas, and Teva Pharma and participated in speaker panels for Amgen, Menarini, AstraZeneca, Bayer, Alexion and Boehringer Lilly. Additionally, he serves on the editorial board for the Journal of Onco-Nephrology . M.A.P. serves as co-Editor-in-Chief of the Journal of Onco-Nephrology , Deputy Editor of Kidney360 and AKI Series Editor of Clinical Nephrology . He serves on editorial boards for Kidney International , KI Reports , the Journal of Nephrology and the American Journal of Medicine . D.R. served on advisory boards of Novartis and Alexion, had teaching honorariums from GSK, BMS, Roche, Novartis and Alexion, and is an UpToDate contributor. C.R. reports serving as Editor-in-Chief of Blood Purification and Cardiorenal Medicine and serving as speaker and having consultancy agreements with AstraZeneca, Aferetica, Asahi, Bayer, B. Braun, Baxter, bioMérieux, CytoSorbents, GE, Medica and Jafron. E.S. acts as a consultant for D.E. Shaw Research and serves on the Advisory Board for Mallinckrodt Pharmaceuticals. B.S. is Theme Editor for onconephrology for the Clinical Kidney Journal and on the editorial board of the Journal of Onco-Nephrology and Glomerular Diseases . V.Tesař is on the editorial board of the Clinical Kidney Journal and is Editor-in-Chief of Frontiers in Nephrology . He also served on the advisory board or received honoraria from AstraZeneca, Boehringer Ingelheim, Novartis, Otsuka, Travere and Vera. V.Torres serves as Academic Editor for PLoS One and is coordinator of the GFR Research Group of the American Society of Onconephrology. R.W. serves as an Associate Editor for the Journal of Onco-Nephrology and the Clinical Kidney Journal . B.T.W. serves as a consultant for Otsuka. D.Z.-O. reports research support from the NIH NCI R01CA291827, R01CA243014, R44CA268314, R44CA232954, R01DK138101. She has intellectual property with Galera Therapeutics and Perspective Therapeutics outside the submitted work. A.D.R., D.E.G., S.L., A.R., A.W. and M.H.R. declare no competing interests.

Free to read: This content has been made available to all.